albuterol (Ventolin) vs Vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline

albuterol (Ventolin)

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule
Weak signal

NCT00144846 · Phase 3 · completed

Although the registry describes 80 participants as randomized and double-blind, it lists only a single albuterol arm with no placebo or active comparator. The primary endpoint was safety, and no results are posted, so the study cannot provide a controlled comparison of treatment benefit.

Next expected readout: April 2027 · NCT06433921 (registry estimate)

No aligned efficacy figure on record for this race.

Vilanterol

Developed by GlaxoSmithKline

Phase 3 in Asthmasmall molecule
Partial signal

NCT00381667 · Phase 2 · completed

The study was randomized, double-blind, and placebo-controlled, but enrolled only 14 participants. Its primary outcomes included lung-function and safety measurements rather than a hard clinical endpoint, and the primary comparison cannot be assessed because results have not been posted.

Reported efficacy

Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) (mixed)

Result source: NCT00600171

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointalbuterol (Ventolin)Vilanterol
Severe exacerbations, annualised rate—Not posted · NCT06657066—Not reported
Trough FEV1, change0.1 vs 0.0vs ADVAIR DISKUS200 mcg · wk 26 · n 120NCT02175771
14 other results
  • 0.1 vs 0.0 200/12.5 mcg · wk 26 · n 130 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100 mcg · wk 26 · n 123 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100/12.5 mcg · wk 26 · n 119 · Phase 3 · secondary NCT02175771
  • 0.3 vs 0.1 100 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 50 mcg · wk 12 · n 100 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.2 vs 0.1 25 mcg · wk 12 · n 97 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.2 vs 0.1 12.5 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
0.3 vs 0.1+0.1 vs placebo25 µg · wk 4 · n 99NCT00600171
8 other results
  • 0.3 vs 0.1 50 µg · wk 4 · n 100 · Phase 2 · primary NCT00600171
  • 0.3 vs 0.1 12.5 µg · wk 4 · n 97 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 6.25 µg · wk 4 · n 99 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 3 µg · wk 4 · n 98 · Phase 2 · primary NCT00600171
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767
ACQ-5, change—Not posted · NCT06657066—Not reported
OCS dose reduction—Not posted · NCT06657066—Not reported

Severe exacerbations, annualised rate

albuterol (Ventolin)
—Not posted · NCT06657066
Vilanterol
—Not reported

Trough FEV1, change

albuterol (Ventolin)
0.1 vs 0.0vs ADVAIR DISKUS200 mcg · wk 26 · n 120NCT02175771
14 other results
  • 0.1 vs 0.0 200/12.5 mcg · wk 26 · n 130 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100 mcg · wk 26 · n 123 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100/12.5 mcg · wk 26 · n 119 · Phase 3 · secondary NCT02175771
  • 0.3 vs 0.1 100 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 50 mcg · wk 12 · n 100 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.2 vs 0.1 25 mcg · wk 12 · n 97 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.2 vs 0.1 12.5 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
Vilanterol
0.3 vs 0.1+0.1 vs placebo25 µg · wk 4 · n 99NCT00600171
8 other results
  • 0.3 vs 0.1 50 µg · wk 4 · n 100 · Phase 2 · primary NCT00600171
  • 0.3 vs 0.1 12.5 µg · wk 4 · n 97 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 6.25 µg · wk 4 · n 99 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 3 µg · wk 4 · n 98 · Phase 2 · primary NCT00600171
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767

ACQ-5, change

albuterol (Ventolin)
—Not posted · NCT06657066
Vilanterol
—Not reported

OCS dose reduction

albuterol (Ventolin)
—Not posted · NCT06657066
Vilanterol
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. albuterol (Ventolin): 7 of 7 rows · Vilanterol: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricalbuterol (Ventolin)
Rows use multiple source trials
Vilanterol
Rows use multiple source trials
FEV1
absolute change · L
5.96 vs -1.38 placebo La,b,c,d,e
NCT05087693 · Phase 4 · registry result, not featured evidence
show 1 more dose
6.98 vs -1.38 placebo L
NCT05087693 · Phase 4 · registry result, not featured evidence
-0.227 vs -0.372 placebo L @ 4.14wk100/25 µg ODb,c,d,e
NCT01128569 · Phase 2 · registry result, not featured evidence
FEV1 Wm0 24 h
absolute change · L
0.048 vs -0.025 placebo L @ 2wk250 µg QDa,c,d
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
show 6 more doses
0.094 vs -0.025 placebo L @ 2wk125 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0.092 vs -0.025 placebo L @ 2wk62.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0.043 vs -0.025 placebo L @ 2wk31.25 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0.077 vs -0.025 placebo L @ 2wk31.25 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0.097 vs -0.025 placebo L @ 2wk15.6 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0.06 vs -0.025 placebo L @ 2wk15.6 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
3.188 vs 2.811 placebo L @ 2wk100/25 µg AMa,c,d
NCT01287065 · Phase 2 · registry result, not featured evidence
show 1 more dose
3.233 vs 2.811 placebo L @ 2wk100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
Rescue-free 24-h Period
percent change · % of baseline
24.07% (n=102) vs 21.3% (n=102) placebo @ 12wk100 mcga,f,c,d
NCT01479621 · Phase 2 · registry result, not featured evidence
show 3 more doses
28.06% (n=102) vs 21.3% (n=102) placebo @ 12wk50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
31.76% (n=101) vs 21.3% (n=102) placebo @ 12wk25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
34.08% (n=102) vs 21.3% (n=102) placebo @ 12wk12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
21.7% (n=115) vs 14.6% (n=115) placebo @ 12wk25 µg ODf,c,d
NCT01181895 · Phase 3 · registry result, not featured evidence
Dropout rate
10%100 mg SCg
NCT04276233 · Phase 4 · registry result, not featured evidence
show 38 more results
—Exercising in Filtered Air Followi
NCT05087693 · Phase 4 · registry result, not featured evidence
—Exercising in Ozone Following Salb
NCT05087693 · Phase 4 · registry result, not featured evidence
16.7%
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
4.8%100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
—
NCT01471340 · Phase 4 · registry result, not featured evidence · pooled
7.7%50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
11.1%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
7.3%200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
2.2%100/10 mcg BID
NCT02741271 · Phase 3 · registry result, not featured evidence
—
NCT02502734 · Phase 3 · registry result, not featured evidence
—200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5.7%
NCT01687296 · Phase 3 · registry result, not featured evidence
12.6%200 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
16%100 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
18.5%160 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
18.3%80 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
16.4%40 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
—800 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—250 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—58 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
5.1%250 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
9.3%125 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
5.9%31.25 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
2%31.25 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
—800 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
7.9%25 µgh
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
4.9%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
9.9%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
16.8%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12.2%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
21.1%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12.4%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
18.4%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1%100 mg SCg
NCT04276233 · Phase 4 · registry result, not featured evidence
show 38 more results
—Exercising in Filtered Air Followi
NCT05087693 · Phase 4 · registry result, not featured evidence
—Exercising in Ozone Following Salb
NCT05087693 · Phase 4 · registry result, not featured evidence
—
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
—100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
—
NCT01471340 · Phase 4 · registry result, not featured evidence · pooled
1.8%50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
1.8%200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
—100/10 mcg BID
NCT02741271 · Phase 3 · registry result, not featured evidence
—
NCT02502734 · Phase 3 · registry result, not featured evidence
—200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—
NCT01687296 · Phase 3 · registry result, not featured evidence
1.7%200 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
1.7%100 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
—160 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
—80 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
—40 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
—800 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—250 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—58 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%250 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%31.25 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
—800 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
1%25 µgh
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
0%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
1%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.9%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
0.9%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Serious AEs
3%100 mg SCg
NCT04276233 · Phase 4 · registry result, not featured evidence
show 38 more results
0%Exercising in Filtered Air Followi
NCT05087693 · Phase 4 · registry result, not featured evidence
0%Exercising in Ozone Following Salb
NCT05087693 · Phase 4 · registry result, not featured evidence
4.2%
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
11%100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
2.3%
NCT01471340 · Phase 4 · registry result, not featured evidence · pooled
0.5%50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
3.6%200/62.5/25 mcg
NCT03184987 · Phase 3 · registry result, not featured evidence
1.1%100/10 mcg BID
NCT02741271 · Phase 3 · registry result, not featured evidence
0%
NCT02502734 · Phase 3 · registry result, not featured evidence
9.8%200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
6.4%200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5%100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5.5%100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
0.8%
NCT01687296 · Phase 3 · registry result, not featured evidence
3.4%200 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
2.5%100 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
0.6%160 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
1.6%80 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
1.3%40 µg
NCT00384189 · Phase 3 · registry result, not featured evidence
0%800 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
0%250 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
0%58 μg
NCT02479412 · Phase 2 · registry result, not featured evidence
1.9%100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
1%50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0.7%250 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%31.5 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—31.25 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
3.3%200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
0%800 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
0%25 µgh
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
0%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.9%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
—25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
0%100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
0%25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mg SCg
pyrexia 5%
headache 3%
oropharyngeal pain 3%
NCT04276233 · Phase 4 · registry result, not featured evidence
show 34 more results
100 mg SC
headache 28.3%
viral upper respiratory tract infection 16.6%
bronchitis 13.1%
NCT02654145 · Phase 4 · registry result, not featured evidence
asthma 0.1%
dry mouth 0.1%
dysphonia 0.1%
NCT01471340 · Phase 4 · registry result, not featured evidence · pooled
50/250 mcg
headache 10.4%
nasopharyngitis 8.1%
bronchitis 5.4%
NCT00363480 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
nasopharyngitis 27.7%
pharyngitis 10.6%
bronchitis 8.5%
NCT03184987 · Phase 3 · registry result, not featured evidence
100/62.5/25 mcg to 200/62.5/25 mcg
bronchitis 22.2%
dysgeusia 22.2%
nasopharyngitis 22.2%
NCT03184987 · Phase 3 · registry result, not featured evidence
200/62.5/25 mcg
nasopharyngitis 32.7%
dysgeusia 10.9%
eczema 9.1%
NCT03184987 · Phase 3 · registry result, not featured evidence
100/10 mcg BID
asthma 11%
upper respiratory tract infection 9.9%
influenza 5.5%
NCT02741271 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.9% (placebo 8.3%)
headache 5.2% (placebo 13.3%)
cough 3.4% (placebo 5%)
NCT02502734 · Phase 3 · registry result, not featured evidence
200/12.5 mcg
upper respiratory tract infection 18%
sinusitis 10.5%
nasopharyngitis 9%
NCT02175771 · Phase 3 · registry result, not featured evidence
200 mcg
upper respiratory tract infection 13.6%
cough 10.4%
nasopharyngitis 10.4%
NCT02175771 · Phase 3 · registry result, not featured evidence
100/12.5 mcg
upper respiratory tract infection 17.5%
nasopharyngitis 12.5%
cough 11.7%
NCT02175771 · Phase 3 · registry result, not featured evidence
100 mcg
upper respiratory tract infection 18.1%
nasopharyngitis 13.4%
sinusitis 11.8%
NCT02175771 · Phase 3 · registry result, not featured evidence
white blood cell count increased 0.8%
NCT01687296 · Phase 3 · registry result, not featured evidence
200 µg OD
headache 12.6%
nasopharyngitis 12.6%
bronchitis 6.7%
NCT01431950 · Phase 3 · registry result, not featured evidence
100 µg OD
bronchitis 11.8%
nasopharyngitis 11.8%
headache 10.1%
NCT01431950 · Phase 3 · registry result, not featured evidence
160 µg
pharyngitis 5.2% (placebo 4.8%)
upper respiratory tract infection 5.2% (placebo 3.4%)
nasopharyngitis 4.2% (placebo 2.1%)
NCT00384189 · Phase 3 · registry result, not featured evidence
80 µg
upper respiratory tract infection 6.4% (placebo 3.4%)
pharyngitis 5.8% (placebo 4.8%)
nasopharyngitis 3.2% (placebo 2.1%)
NCT00384189 · Phase 3 · registry result, not featured evidence
40 µg
nasopharyngitis 6.2% (placebo 2.1%)
upper respiratory tract infection 5.9% (placebo 3.4%)
pharyngitis 4.6% (placebo 4.8%)
NCT00384189 · Phase 3 · registry result, not featured evidence
800 μg
nasopharyngitis 11.8% (placebo 15.4%)
diarrhoea 8.8% (placebo 0%)
headache 5.9% (placebo 0%)
NCT02479412 · Phase 2 · registry result, not featured evidence
250 μg
headache 8.8% (placebo 0%)
nasopharyngitis 5.9% (placebo 15.4%)
asthma 2.9% (placebo 1.9%)
NCT02479412 · Phase 2 · registry result, not featured evidence
58 μg
nasopharyngitis 11.8% (placebo 15.4%)
gastroenteritis 8.8% (placebo 0%)
cough 5.9% (placebo 1.9%)
NCT02479412 · Phase 2 · registry result, not featured evidence
100 mcg
upper respiratory tract infection 4.9% (placebo 2.9%)
nasopharyngitis 2.9% (placebo 4.8%)
NCT01479621 · Phase 2 · registry result, not featured evidence
50 mcg
nasopharyngitis 6.7% (placebo 4.8%)
upper respiratory tract infection 2.9% (placebo 2.9%)
NCT01479621 · Phase 2 · registry result, not featured evidence
25 mcg
nasopharyngitis 4.8% (placebo 4.8%)
upper respiratory tract infection 1.9% (placebo 2.9%)
NCT01479621 · Phase 2 · registry result, not featured evidence
12.5 mcg
upper respiratory tract infection 6.8% (placebo 2.9%)
nasopharyngitis 3.9% (placebo 4.8%)
NCT01479621 · Phase 2 · registry result, not featured evidence
250 µg QD
headache 4.4% (placebo 1.6%)
product taste abnormal 3.7% (placebo 0%)
nasopharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
125 µg QD
headache 3.1% (placebo 1.6%)
product taste abnormal 3.1% (placebo 0%)
nasopharyngitis 2.3% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
62.5 µg QD
headache 3.8% (placebo 1.6%)
pharyngitis 3.8% (placebo 0.8%)
nasopharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
31.5 µg QD
headache 2.9% (placebo 1.6%)
product taste abnormal 1.4% (placebo 0%)
pharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
31.25 µg BID
headache 4.5% (placebo 1.6%)
nasopharyngitis 1.5% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
15.6 µg BID
nasopharyngitis 3.2% (placebo 0.8%)
headache 1.6% (placebo 1.6%)
pharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
15.6 µg QD
headache 3.8% (placebo 1.6%)
nasopharyngitis 2.3% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
200 ug
catheter site haematoma 16.7%
headache 10%
abdominal pain 6.7%
NCT06433908 · Phase 1 · registry result, not featured evidence
800 ug
catheter site related reaction 30%
headache 16.7%
cough 10%
NCT06433908 · Phase 1 · registry result, not featured evidence
25 µgh
headache 6.9% (placebo 7.8%)
upper respiratory tract infection 2% (placebo 2%)
nasopharyngitis 0% (placebo 3.9%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 13 more results
50 µg
headache 7.8% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 2% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12.5 µg
headache 9% (placebo 7.8%)
upper respiratory tract infection 3% (placebo 2%)
nasopharyngitis 0% (placebo 3.9%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
6.25 µg
headache 6.9% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 1% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
3 µg
headache 11.9% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 2% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
25 µg OD
headache 8.7% (placebo 4.3%)
nasopharyngitis 7.8% (placebo 10.3%)
oropharyngeal pain 5.2% (placebo 6%)
NCT01181895 · Phase 3 · registry result, not featured evidence
12.5 OD
nasopharyngitis 8.8% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
25 OD
nasopharyngitis 7.9% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
6.25 OD
nasopharyngitis 7% (placebo 7%)
headache 5.3% (placebo 3.5%)
influenza 3.5% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
100/25 µg AM
headache 25% (placebo 26.1%)
nasopharyngitis 12.5% (placebo 13%)
dysmenorrhoea 4.2% (placebo 0%)
NCT01287065 · Phase 2 · registry result, not featured evidence
100/25 µg PM
headache 32% (placebo 26.1%)
gastroenteritis 8% (placebo 0%)
nasopharyngitis 8% (placebo 13%)
NCT01287065 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 55.6% (placebo 40.7%)
nasopharyngitis 11.1% (placebo 7.4%)
oropharyngeal pain 11.1% (placebo 7.4%)
NCT01128595 · Phase 2 · registry result, not featured evidence
25 µg
upper respiratory tract infection 11.1% (placebo 0%)
headache 7.4% (placebo 7.7%)
pyrexia 7.4% (placebo 0%)
NCT01453296 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 9.8% (placebo 17.6%)
dysphonia 3.9% (placebo 0%)
mouth ulceration 3.9% (placebo 0%)
NCT01128569 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 4.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fTrial phases differ: Phase 3 versus Phase 2.
  7. gPopulation comparability has not been reviewed for 31 of these studies.
  8. hPopulation comparability has not been reviewed for 12 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

albuterol (Ventolin)

Asthma Exacerbation Occurrence 8% (n=100) @ 24wk100 mg SC
event count · % of participants
No placebo or comparator arm
NCT04276233 · Phase 4 · registry result, not featured evidence · converted to % from 8 Participants as posted
Asthma Exacerbation Hospitalization Occurrence 2% (n=100) @ 24wk100 mg SC
event count · % of participants
No placebo or comparator arm
NCT04276233 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted
show 1 more result
2% (n=100) @ 24wk*100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted
FEV1 0.284 L @ 24wk200 µg OD
absolute change · L
No placebo or comparator arm
NCT01431950 · Phase 3 · registry result, not featured evidence
show 6 more results
0.081 L @ 24wk100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence
0.055 L @ 24wk100 mg SC
NCT04276233 · Phase 4 · registry result, not featured evidence
0.208 L @ 24wk100 µg OD
NCT01431950 · Phase 3 · registry result, not featured evidence
0.133 L @ 4wk50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
0.212 L @ 8wk50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
0.181 L @ 12wk50/250 mcg
NCT00363480 · Phase 4 · registry result, not featured evidence
ACQ-5 -0.69 score @ 24wk100 mg SC
absolute change · score
No placebo or comparator arm
NCT04276233 · Phase 4 · registry result, not featured evidence
show 1 more result
-1.45 score @ 32wk100 mg SC
NCT02654145 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 13.67 L/min @ 24wk100 mg SC
absolute change · L/min
No placebo or comparator arm
NCT04276233 · Phase 4 · registry result, not featured evidence
FVC Change 0.77 vs -1.37 placebo L
absolute change · L
NCT05087693 · Phase 4 · registry result, not featured evidence
show 1 more result
0.39 vs -1.37 placebo L
NCT05087693 · Phase 4 · registry result, not featured evidence
Exhaled no Change Ppb 9.01 parts per billion (ppb) @ 24wk
absolute change · parts per billion (ppb)
No placebo or comparator arm
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
Asthma Symptom -0.59 score @ 12wk50/250 mcg
absolute change · score
No placebo or comparator arm
NCT00363480 · Phase 4 · registry result, not featured evidence
show 1 more result
0.83 score @ 24wk
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
Rescue Medication Use -0.933 count @ 12wk50/250 mcg
absolute change · count
No placebo or comparator arm
NCT00363480 · Phase 4 · registry result, not featured evidence
show 1 more result
1.16 count @ 24wk
NCT03924635 · Phase 4 · registry result, not featured evidence · combination
SGRQ Total -19 score @ 32wk100 mg SC
absolute change · score
No placebo or comparator arm
NCT02654145 · Phase 4 · registry result, not featured evidence
Severe Exacerbation Rate Annualized 1.18 per year @ 32wk100 mg SC
event rate · per year
No placebo or comparator arm
NCT02654145 · Phase 4 · registry result, not featured evidence
Time-to-First Serious Asthma Outcome 39 vs 32 MF Serious asthma outcomes @ 26wk
absolute value · Serious asthma outcomes
NCT01471340 · Phase 4 · registry result, not featured evidence · pooled

+ 37 further endpoints in the CSV export.

Vilanterol

FEV1 AUC0-24 0.33 vs 0.137 placebo L @ 0.14wk25 µg
absolute change · L
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 9 more results
0.315 vs 0.149 placebo L @ 4wk25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.352 vs 0.137 placebo L @ 0.14wk50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.321 vs 0.149 placebo L @ 4wk50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.267 vs 0.137 placebo L @ 0.14wk12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.292 vs 0.149 placebo L @ 4wk12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.215 vs 0.137 placebo L @ 0.14wk6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.253 vs 0.149 placebo L @ 4wk6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.239 vs 0.137 placebo L @ 0.14wk3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.3 vs 0.149 placebo L @ 4wk3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Evening PEF 34 vs 0.4 placebo L/min25 µg
absolute change · L/min
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 5 more results
24.9 vs 11 placebo L/min @ 12wk25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
38.4 vs 0.4 placebo L/min50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
28.9 vs 0.4 placebo L/min12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
24.5 vs 0.4 placebo L/min6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
14 vs 0.4 placebo L/min3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Morning PEF 38.1 vs 1.9 placebo L/min25 µg
absolute change · L/min
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 5 more results
28 vs 14.2 placebo L/min @ 12wk25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
44 vs 1.9 placebo L/min50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
34.2 vs 1.9 placebo L/min12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
26.8 vs 1.9 placebo L/min6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
18.7 vs 1.9 placebo L/min3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Symptom-free 24 h Periods 36.4% (n=101) vs 14.2% (n=98) placebo25 µg
absolute change · percentage points
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more results
32.3% (n=102) vs 14.2% (n=98) placebo50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
26.8% (n=98) vs 14.2% (n=98) placebo12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
23.6% (n=101) vs 14.2% (n=98) placebo6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
22.6% (n=99) vs 14.2% (n=98) placebo3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Rescue-free 24 h Periods 43.4% (n=101) vs 15% (n=99) placebo25 µg
absolute change · percentage points
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more results
34% (n=102) vs 15% (n=99) placebo50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
29.6% (n=98) vs 15% (n=99) placebo12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
27.3% (n=101) vs 15% (n=99) placebo6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
25.8% (n=99) vs 15% (n=99) placebo3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Symptom-free 24-h Period 19.4% (n=115) vs 12.7% (n=115) placebo @ 12wk25 µg OD
percent change · % of baseline
NCT01181895 · Phase 3 · registry result, not featured evidence
show 3 more results
19.7% (n=110) vs 9.9% (n=113) placebo @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
18.3% (n=112) vs 9.9% (n=113) placebo @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
10.1% (n=113) vs 9.9% (n=113) placebo @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
FEV1 0.33 vs 0.301 placebo L @ 12wk25 µg OD
absolute change · L
24 hours, n= 95, 101, 100
NCT01181895 · Phase 3 · registry result, not featured evidence
Evening PEF Change L/Min 220.3 vs 215.9 placebo L/min @ 4wk25 µg OD
absolute change · L/min
NCT01573767 · Phase 2 · registry result, not featured evidence
show 5 more results
11.1 vs 5.9 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
222.4 vs 215.9 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.7 vs 5.9 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
221.4 vs 215.9 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
9.4 vs 5.9 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
Morning PEF Change L/Min 13.7 vs 6.4 placebo L/min @ 4wk25 µg OD
absolute change · L/min
NCT01573767 · Phase 2 · registry result, not featured evidence
show 5 more results
14.4 vs 7.4 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.9 vs 6.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
17 vs 7.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12 vs 6.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.3 vs 7.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
FEV1 Trough 3.191 vs 2.788 placebo L @ 2wk100/25 µg AM
absolute change · L
AM, n=22, 24, 25
NCT01287065 · Phase 2 · registry result, not featured evidence
show 1 more result
3.285 vs 2.788 placebo L @ 2wk100/25 µg PM
AM, n=22, 24, 25
NCT01287065 · Phase 2 · registry result, not featured evidence
FEV1 Evening Trough 3.153 vs 2.879 placebo L @ 2wk100/25 µg AM
absolute change · L
PM, n=23, 24, 25
NCT01287065 · Phase 2 · registry result, not featured evidence
show 1 more result
3.188 vs 2.879 placebo L @ 2wk100/25 µg PM
PM, n=23, 24, 25
NCT01287065 · Phase 2 · registry result, not featured evidence
LAR Min FEV1 Change -0.216 vs -0.731 placebo L @ 3wk100/25 µg OD
absolute change · L
NCT01128595 · Phase 2 · registry result, not featured evidence

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Ventolin)'s landscape · Vilanterol's landscape